Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inetagugene geperpavec - Krystal Biotech

Next Previous
Drug Profile

Inetagugene geperpavec - Krystal Biotech

Alternative Names: HSV1-TGM1; KB-105

Latest Information Update: 05 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Krystal Biotech
  • Class Gene therapies; Skin disorder therapies
  • Mechanism of Action Gene transference; Transglutaminase 1 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ichthyosis
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Ichthyosis

Most Recent Events

  • 29 Feb 2024 Krystal Biotech has patent protection for the pharmaceutical composition comprising of replication defective HSV-1 vector encoding TGM and methods of delivering TGM in USA before February 2024
  • 29 Feb 2024 Krystal Biotech has patent protection for the pharmaceutical composition comprising of herpes virus vector encoding TGM in Australia before February 2024
  • 23 Feb 2023 Krystal Biotech plans phase II trial in Icthyosis (In infants, In adolescents, In children, In adults, In the elderly) in USA in March 2023 (Topical, Gel) (NCT05735158)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top